Acumen Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $178 | $0 |
Gross Profit | -45 | 89 | -45 | |
EBITDA | -41,750 | -27,728 | -36,073 | -28,693 |
EBIT | -27,773 | -36,117 | -28,738 | |
Net Income | -40,950 | -28,796 | -37,154 | -29,765 |
Net Change In Cash | 0 | 0 | 178 | 0 |
Free Cash Flow | -31,841 | -34,200 | -27,215 | -24,596 |
Cash | 36,810 | 30,159 | 35,627 | 33,184 |
Basic Shares | 60,573 | 60,525 | 60,013 | 60,079 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $1,436 |
Gross Profit | -178 | -42,318 | -169 | -4 |
EBITDA | -98,083 | -51,606 | -42,687 | -19,580 |
EBIT | -98,261 | -51,790 | -42,856 | -19,584 |
Net Income | -102,329 | -52,371 | -42,856 | -100,606 |
Net Change In Cash | 0 | 0 | 0 | 1,436 |
Cost of Revenue | 7,939 | 78,385 | ||
Free Cash Flow | -86,231 | -43,085 | -35,314 | -18,001 |
Cash | 35,627 | 66,886 | 130,101 | 122,162 |
Basic Shares | 60,013 | 48,609 | 40,601 | 38,266 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.68 |
2025-03-31 | -$0.48 |
2024-12-31 | -$0.62 |
